CN102245180A - 用于治疗改变的α-突触核蛋白功能的组合物和方法 - Google Patents

用于治疗改变的α-突触核蛋白功能的组合物和方法 Download PDF

Info

Publication number
CN102245180A
CN102245180A CN2009801502638A CN200980150263A CN102245180A CN 102245180 A CN102245180 A CN 102245180A CN 2009801502638 A CN2009801502638 A CN 2009801502638A CN 200980150263 A CN200980150263 A CN 200980150263A CN 102245180 A CN102245180 A CN 102245180A
Authority
CN
China
Prior art keywords
alkyl
alkenyl
substituted
disease
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801502638A
Other languages
English (en)
Chinese (zh)
Inventor
A·B·曼宁-伯格
B·舒尔
J·W·朗斯顿
C·A·零伍德
M·S·麦克格拉斯
A·A·阿茨希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Original Assignee
Hospital for Sick Children HSC
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC, Parkinsons Institute, Neuraltus Pharmaceuticals Inc filed Critical Hospital for Sick Children HSC
Publication of CN102245180A publication Critical patent/CN102245180A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801502638A 2008-11-14 2009-09-04 用于治疗改变的α-突触核蛋白功能的组合物和方法 Pending CN102245180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
US61/199,243 2008-11-14
PCT/US2009/056116 WO2010056413A2 (en) 2008-11-14 2009-09-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION

Publications (1)

Publication Number Publication Date
CN102245180A true CN102245180A (zh) 2011-11-16

Family

ID=42170611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801502638A Pending CN102245180A (zh) 2008-11-14 2009-09-04 用于治疗改变的α-突触核蛋白功能的组合物和方法

Country Status (9)

Country Link
US (2) US20120052053A1 (enExample)
EP (1) EP2361089A4 (enExample)
JP (2) JP2012508740A (enExample)
CN (1) CN102245180A (enExample)
AU (1) AU2009314447A1 (enExample)
BR (1) BRPI0920498A2 (enExample)
CA (1) CA2745451A1 (enExample)
GB (1) GB2480159A (enExample)
WO (1) WO2010056413A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
CN105748460A (zh) * 2016-04-07 2016-07-13 于昉 一种治疗老年痴呆的药物
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
WO2017167168A1 (en) * 2016-03-28 2017-10-05 Syneurx International (Taiwan) Corp. Compositions containing tannic acids and uses thereof
WO2018024245A1 (en) * 2016-08-04 2018-02-08 Guochuan Emil Tsai Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN115417789A (zh) * 2022-09-03 2022-12-02 郑州大学 一种治疗帕金森氏病的新化合物、其制备方法以及复方药物组合物和应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505374A (ja) * 2007-11-29 2011-02-24 ザ・ホスピタル・フォー・シック・チルドレン リソソーム障害を処置するための組成物および方法
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2739304A4 (en) * 2011-08-04 2015-06-03 Univ Ramot PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CA3018745A1 (en) * 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
KR20200097255A (ko) * 2017-12-07 2020-08-18 신유알엑스 인터내셔널 (타이완) 코포레이션 탄닌산 조성물을 제조하기 위한 개선된 풍부화 방법
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US11766423B2 (en) 2018-03-01 2023-09-26 The Johns Hopkins University 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
KR102102868B1 (ko) * 2019-05-14 2020-04-23 주식회사 노브메타헬스 고시페틴(Gossypetin)을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
KR20230004765A (ko) 2020-04-23 2023-01-06 신유알엑스 인터내셔널 (타이완) 코포레이션 화합물 및 이의 약학적 용도
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
KR20240023004A (ko) * 2022-08-12 2024-02-20 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
CN104771402A (zh) * 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
DK1860101T3 (da) * 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
AU2007260812B2 (en) * 2006-06-23 2012-08-16 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
US10105378B2 (en) 2016-03-28 2018-10-23 SynenRx International (Taiwan) Corp. Enrichment methods for preparing tannic acid compositions
WO2017167168A1 (en) * 2016-03-28 2017-10-05 Syneurx International (Taiwan) Corp. Compositions containing tannic acids and uses thereof
RU2715703C1 (ru) * 2016-03-28 2020-03-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Композиции, содержащие дубильные кислоты и их применение
US10265336B2 (en) 2016-03-28 2019-04-23 Syneurx International (Taiwan) Corp. Compositions containing tannic acids and uses thereof
CN108348557A (zh) * 2016-03-28 2018-07-31 心悦生医股份有限公司 含有鞣酸的组合物及其用途
CN105748460A (zh) * 2016-04-07 2016-07-13 于昉 一种治疗老年痴呆的药物
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
WO2018024245A1 (en) * 2016-08-04 2018-02-08 Guochuan Emil Tsai Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10617660B2 (en) 2016-08-04 2020-04-14 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
IL264534B (en) * 2016-08-04 2022-08-01 Syneurx Int Taiwan Corp Preparations containing a benzoate compound and tannic acid for the treatment of central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
CN115417789A (zh) * 2022-09-03 2022-12-02 郑州大学 一种治疗帕金森氏病的新化合物、其制备方法以及复方药物组合物和应用
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Also Published As

Publication number Publication date
JP2012508740A (ja) 2012-04-12
GB201108374D0 (en) 2011-06-29
JP2015127343A (ja) 2015-07-09
CA2745451A1 (en) 2010-05-20
EP2361089A4 (en) 2012-08-22
AU2009314447A1 (en) 2010-05-20
EP2361089A1 (en) 2011-08-31
US20120052053A1 (en) 2012-03-01
GB2480159A (en) 2011-11-09
US20150044193A1 (en) 2015-02-12
BRPI0920498A2 (pt) 2019-09-24
WO2010056413A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CN102245180A (zh) 用于治疗改变的α-突触核蛋白功能的组合物和方法
US8252789B2 (en) Compositions and methods for treating lysosomal disorders
Lin et al. N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
KR102076585B1 (ko) 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
Jeyakumar et al. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis
Platt et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy
US20140235649A1 (en) Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
Mei et al. Sphingolipid metabolism in brain insulin resistance and neurological diseases
EP2490712B1 (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
US20160075651A1 (en) Glycolipid inhibition using iminosugars
US7662838B2 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP3989962B1 (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
LeVine et al. Substrate reduction therapy for krabbe disease: exploring the repurposing of the antibiotic D-Cycloserine
AU2015247859B2 (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
AU2014265137A1 (en) Compositions and methods for the treatment of altered alpha-synuclein function
Dobi et al. Effect of CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor on lipid metabolism in human bronchial epithelial cells
WO2009040816A1 (en) Methods of treating lysosomal storage disorders
HK1175400B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20111116

RJ01 Rejection of invention patent application after publication